Employees: 738
Size CryoPort (CYRX) is a United States Health Care company (Air Freight/Couriers) with a market value of $1.02B, the 2219th largest of 3,085 United States companies the cockpit tracks. Shares closed at $20.17 on 18 Nov 2026.
Performance Over six months the shares gained 43.4%, against +7.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 1.1% over the last twelve months (peer median +10.4%); the operating margin is -20.0% (peer median -5.2%).
Valuation It trades at 4.7× enterprise value to sales against a peer median of 4.5× (6th most expensive of 13).
Capital Return on invested capital runs 21.1 points below its cost of capital (12.9% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $192M | $176M | $157M | $233M | $237M |
| Revenue growth | — | +12% | -33% | -2% | — |
| Gross profit | $77.3M | $70.4M | $57.1M | $83.0M | $88.8M |
| EBITDA | -$12.7M | -$16.8M | -$35.5M | -$31.2M | -$6.97M |
| Net income | -$37.1M | -$38.7M | -$115M | -$99.6M | -$37.3M |
| Free cash flow | -$18.8M | -$25.0M | -$33.6M | -$39.5M | -$24.0M |
| Capital expenditure | $30.9M | $19.5M | $21.3M | $44.9M | $24.2M |
| Total debt | $232M | $231M | $243M | $416M | $436M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CYRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.7% | -4.8% | 2nd highest of 21 |
| 6-month return | +43.4% | +7.4% | 3rd highest of 20 |
| Distance from 52-week high | -7.4% | -31.9% | highest of 21 |
| Revenue growth (TTM) | +1.1% | +10.4% | 5th lowest of 11 |
| Operating margin | -20.0% | -5.2% | 5th lowest of 13 |
| EV / Sales | 4.7× | 4.5× | 6th most expensive of 13 |
| ROIC minus cost of capital | -21.1 pp | -8.4 pp | 4th lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CryoPort CYRX | United States | $1.02B | +43% | +1% | -20% | 4.7× | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a | n/a |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | 2.1× | 57.7% | +40.6% |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | 0.9× | 16.8% | +25.2% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | 8.3× | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 11.1× | 18.5% | +21.5% |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | 4.3× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 1.7× | 5.9% | +3.6% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 17.3× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | 4.7× | n/a | n/a |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 1.9× | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 1.8× | 6.3% | +7.7% |